10:14 EDT Gilead (GILD) down 2% to $111.14 after FDA placed hold on some HIV trials
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences: Strong Market Position and Growth Potential Drive Buy Rating
- Gilead Sciences’ Oncology Advancements: Trodelvy’s Potential to Boost Stock Value
- Gilead Sciences: Promising Pipeline and Strategic Advancements Justify Buy Rating
- Gilead Sciences: Buy Rating Driven by Promising HIV Treatment Pipeline and Strategic Growth Prospects
- Gilead Sciences: Buy Rating Affirmed on Promising Oncology Pipeline and Trodelvy’s Potential as New Standard of Care
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue